Empowering mobility

and independence.

ABLE is a powered orthosis for spinal cord injured individuals that allows them to stand up from the wheelchair and walk again.

ABLE is the first lightweight, easy-to-use and affordable exoskeleton for people with lower-limb paralysis, that restores the ability to walk naturally and intuitively.

It helps in palliating health issues caused by sedentary lifestyle while boosting self-confidence and independence.

ABLE Human Motion ®

Lightweight

ABLE Human Motion ®

Easy-to-use

ABLE Human Motion ®

Affordable

In only 2 years we went from an idea to a functional prototype successfully tested in subjects with spinal cord injury.

2018

· Company Incorporation

· Market Validation 100 interviews with MDs, PTs, and patients

· Proof of Concept Prototype

· Partnership with Institut Guttmann, UPC and Ingenia

2019

· Investor’s ready Business Plan

· Regulatory Strategy Report

· International Advisory Board

· Peer Review Publication

· Patent WO2018073252A1 in National Phases

· Seed Investment Round

· Usability Study with 15 SCI subjects

2020

· Government Grants

· Team Growth: 12 people

· Collaborations with leading rehabilitation institutions

· Prototype ready for Clinical Investigation

· Filed a second Patent

· Multicenter Clinical Investigation (for SCI, hospital use)

· Quality System Implementation

2021

· ISO 13485 Certification

· Manufacturer’s License (AEMPS)

· Exoskeleton Design Freeze

· Comparative Crossover Clinical Trial (vs standard of care)

· Medical Articles published

· Stroke exoskeleton Pilot Study

· Bridge Investment Round

2022

· ABLE Exoskeleton CE Mark as Class IIa MD

· Multicenter Clinical Investigation (for SCI, home use)

· Clinical Efficacy Trials

· Stroke exoskeleton Clinical Investigation

· Series A Investment Round

2023

· First Sales to Clinical Institutions in ES, GER, Nordics, Benelux

· Clinical Trial in United States

· ABLE Exoskeleton CE Certification for Homecare use

· Agreements with Distributors

2024

· Sales to Clinical Institutions in FRA, ITA, UK, IL

· FDA Clearance

· CE Mark Stroke exoskeleton

· First Sales to End-users

This product is not CE approved yet,
is currently under clinical evaluation.

Coming Soon!

Presales in 2022.

Empowering mobility
and independence.

ABLE is a powered orthosis for spinal cord injured individuals that allows them to stand up from the wheelchair and walk again.

ABLE is the first lightweight, easy-to-use and affordable exoskeleton
for people with lower-limb paralysis, that restores the ability to walk
naturally and intuitively.
It helps in palliating health issues caused by sedentary lifestyle
while boosting self-confidence and independence.
Lightweight

Lightweight

Easy-to-use

Easy-to-use

Affordable

Affordable

In only 2 years we went from an idea,

to a functional prototype successfully tested in subjects with spinal cord injury.

  1. 2018

    • Company Incorporation
    • Market Validation 100 interviews with MDs, PTs, and patients
    • Proof of Concept Prototype
    • Partnership with Institut Guttmann, UPC and Ingenia
  2. 2019

    • Investor’s ready Business Plan
    • Regulatory Strategy Report
    • International Advisory Board
    • Peer Review Publication
    • Patent WO2018073252A1 in National Phases
    • Seed Investment Round
    • Usability Study with 15 SCI subjects
  3. 2020

    • Government Grants
    • Team Growth: 12 people
    • Collaborations with leading rehabilitation institutions
    • Prototype ready for Clinical Investigation
    • Filed a second Patent
    • Multicenter Clinical Investigation (for SCI, hospital use)
    • Quality System Implementation
  4. 2021

    • ISO 13485 Certification
    • Manufacturer’s License (AEMPS)
    • Exoskeleton Design Freeze
    • Comparative Crossover Clinical Trial (vs standard of care)
    • Medical Articles published
    • Stroke exoskeleton Pilot Study
    • Bridge Investment Round
  5. 2022

    • ABLE Exoskeleton CE Mark as Class IIa MD
    • Multicenter Clinical Investigation (for SCI, home use)
    • Clinical Efficacy Trials
    • Stroke exoskeleton Clinical Investigation
    • Series A Investment Round
  6. 2023

    • First Sales to Clinical Institutions in ES, GER, Nordics, Benelux
    • Clinical Trial in United States
    • ABLE Exoskeleton CE Certification for Homecare use
    • Agreements with Distributors
  7. 2024

    • Sales to Clinical Institutions in FRA, ITA, UK, IL
    • FDA Clearance
    • CE Mark Stroke exoskeleton
    • First Sales to End-users
This product is not CE approved yet,
is currently under clinical evaluation.

Coming Soon!

Presales in 2022.

×

¿Te gustaría probar nuestro exoesqueleto?

*Sólo PACIENTES y HOSPITALES.

Para otras comunicaciones, contactar a través del Formulario de Contacto

× ¿Te gustaría probar ABLE?